Key information

This information is provided for the purposes of AIM rule 26

Our Mission

Our Mission is to shape the future of medicine by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms.

Investment Opportunity

  • Avacta’s proprietary Affimer® and pre|CISION™ platforms are delivering a robust portfolio of differentiated therapeutic and diagnostic products that address multiple multi-billion dollar markets.
  • Affimers are engineered alternatives to antibodies that have significant competitive advantages including size, stability, versatility, rapid development and ease of production. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100 billion.
  • Avacta’s Affimer-based rapid Covid-19 antigen test due for commercial roll-out by end Q1.
  • The pre|CISION™ targeted chemotherapy platform releases active chemotherapy directly in the tumour, limiting systemic exposure and side effects associated with many commonly used cancer treatments. Phase I trial for first candidate, AVA6000, due to start by mid-2021.
  • Significant potential of Affimer® drug conjugates to be the next generation cancer treatments. Combination of both platforms allowing immunotherapy to be fused with a chemotherapy in a single molecule.
  • Platforms validated through leading industry partnerships including Moderna, LG Chem, Daewoong Pharma, ADC Therapeutics and POINT Biopharma.
  • The Company plans to generate additional Affimer® and pre|CISION™ drug development candidates in 2021, to further support its growing, innovative pipeline.
  • With its strong balance sheet, the Group expects to deliver major value inflection points from its well-funded therapeutic programmes over the next 12 months and deliver near to medium term revenues from its diagnostic business, driving long-term shareholder value.


  • Build a portfolio of novel, clinically differentiated cancer therapies leveraging the key benefits of the Affimer® and pre|CISION™ platforms.
  • Create a fast-paced, nimble, delivery-focused drug discovery and development organisation to transform Avacta into a clinical stage biotech with multiple clinical programmes and an exciting pre-clinical pipeline.
  • Establish partnerships with global pharmaceutical companies for our technology platforms and pipeline.
  • Grow a profitable revenue stream from Affimer® diagnostics through partnerships and licensing as well as in-house product development.

Significant Shareholdings

Current significant shareholders are as follows:

Premier Miton Group  – 4.66%

Baillie Gifford & Co Limited – 4.63%

Conifer Management, LLC – 2.99%

As at 3rd November 2021 the company has 253,712,353 ordinary shares of 10p each in issue.

2.0%  of the ordinary shares of the Company are not held in public hands.

Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.

There are no restrictions on the transfer of Avacta Group plc’s AIM securities.

Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.

Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.

This information was last updated on 3rd November 2021,


Dr Alastair Smith
Mr Tony Gardiner
Dr Eliot Forster
Dr Trevor Nicholls
Mr Paul Fry
Dr Mark Goldberg


Broker and Nomad – Stifel, 150 Cheapside, London, EC2V 6ET
Auditor – BDO LLP, Newton House, Cambridge Business Park, Cambridge, CB4 0WZ
Solicitor – Walker Morris, 33 Wellington Street, Leeds, LS1 4DL
Registrar – Link Group, 10th floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL.
Investor and Media Relations – FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.